

**PUBBLICAZIONI SU RIVISTE SCIENTIFICHE INTERNAZIONALI** (in ordine cronologico)

1. - “A novel small nucleolar RNA (U16) is encoded inside a ribosomal protein intron and originates by processing of the pre-mRNA”. P. Fragapane, S. Prislei, **A. Michienzi**, E. Caffarelli and I. Bozzoni, (1993). *EMBO J.*, 12, pp.2921-2928
2. -“Two different snoRNA are encoded in introns of the L1 ribosomal protein genes of amphibia and humans”. Prislei S., **Michienzi A.**, Presutti C., Fragapane P., and Bozzoni I., (1993). *Nucleic Acid Research*, 21, pp.5834-5840.
3. - “U1 snRNA-chimeric ribozymes with substrate specificity for the Rev pre-mRNA of HIV”. **Michienzi A.**, S. Prislei, and I. Bozzoni. (1996). *Proc. Natl. Acad. Sci.*, 93, pp.7219-7224.
4. - “Use of adenoviral VAI small RNA as carrier for cytoplasmic delivery of ribozymes”S. Prislei, S.B.C. Buonomo, **A. Michienzi** and I. Bozzoni (1997) *RNA*, 3, pp.1-11
5. - “Inhibition of HIV-1 replication by nuclear chimeric anti-HIV ribozymes in a human T-lymphoblastoid cell line”. **A. Michienzi**, L. Conti, B. Varano, S. Prislei, S. Gessani and I. Bozzoni (1998) *Human Gene Therapy*, 9, pp. 621-628.
6. “The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element”.S. B. C. Buonomo\*, **A. Michienzi\***, F. G. De Angelis, and I. Bozzoni (1999). *RNA*, 5, pp. 993-1002 \* authors equally contributed
7. “A chimeric nucleolar Rev decoy inhibits the HIV replication”.**A. Michienzi**, L. Cagnon, I. Bozzoni and J.J. Rossi (1999). *Nucleic Acids Symp Ser.*, 41, pp.211-214.
- 8.” Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA”. **Alessandro Michienzi**, Laurance Cagnon, Ingrid Bahner, and John J. Rossi (2000). *Proc. Natl. Acad. Sci.*, 97, pp.8955-8960.
- 9.” Intracellular Applications of Ribozymes”. **Alessandro Michienzi** and John J. Rossi (2001) *Methods Enzymol.*, 341, pp:581-96.
- 10.” Ribozymes as Therapeutic Agents and Genetics Tools” Poggi, A., **Michienzi, A.** and Rossi, J.J. (2002) *In Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics*, Taylor and Francis Publishers, London, U.K.
- 11.” A nucleolar TAR decoy inhibitor of HIV-1 replication”.**A. Michienzi**, S. Li, J.A.Zaia, and J. J. Rossi (2002) *Proc. Natl. Acad. Sci.*, 99:14047-14052.
- 12.” Intracellular ribozyme applications.” Castanotto D., Li JR, **Michienzi A**, Langlois MA, Lee NS, Puymirat J, Rossi JJ. (2002) *Biochem Soc Trans.* 30:1140-5.
13. “Novel ribozyme, RNA decoy, and siRNA approaches to inhibition of HIV in a gene therapy setting”. **Alessandro Michienzi**, Danliela Castanotto, Nancy Lee, Shirley Li, John A. Zaia, John J. Rossi. (2003) *Clinical and Applied Immunology Reviews* 3: 223-233.

- 14.** “Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs”. Ming-Jie Li, Gerhard Bauer, Alessandro Michienzi, Jiing-Kuan Yee, Nan-Sook Lee, James Kim, Shirley Li, Daniela Castanotto, John Zaia and John J. Rossi. (2003) ***Molecular Therapy***, 8:196-206
- 15.** “RNA-mediated inhibition of HIV in a gene therapy settings”. Michienzi A , Castanotto D, Lee N, Li S, Zaia JA, Rossi JJ. (2003) ***Ann NY Acad Sci.***, 1002:63-71.
- 16.** A nucleolar localizing Rev binding element inhibits HIV replication. Michienzi A, DeAngelis F, Bozzoni I, Rossi J ***AIDS Research and Therapy***, 2006 3:13.
- 17.** CCL2 down-modulation by selected TLR agonist combinations contributes to Th1 polarization in human dendritic cells. Del Corno M\*, Michienzi A\*, Masotti A, Da Sacco L, Bottazzo GF, Belardelli F, Gessani S. (2009) **Blood**. Jul 23;114(4):796-806. Epub 2009 May 22.  
\*The authors contributed equally to this work.
- 18.** EDITING OF HIV-1 RNA BY THE DOUBLE-STRANDED RNA DEAMINASE ADAR1 STIMULATES VIRAL INFECTION. Margherita Doria, Francesca Neri, Angela Gallo, Maria Giulia Farace and Alessandro Michienzi. ***Nucleic Acids Res.*** 2009, Sep;37(17):5848-58.
- 19.** ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor. Doria M, Tomaselli S, Neri F, Ciafrè SA, Farace MG, Michienzi A\*, Gallo A\*.  
\*The authors contributed equally to this work. ***J Gen Virol.*** 2011 May;92(Pt 5):1228-32. Epub 2011 Feb 2.
- 20.** The HIV-1 Tat protein modulates CD4 expression in human T cells through the induction of miR-222. Orecchini E, Doria M, Michienzi A, Giuliani E, Vassena L, Ciafrè SA, Farace MG, Galardi S. ***RNA Biol.*** 2014;11(4):334-8
- 21.** HIV-1 infection causes a down-regulation of genes involved in ribosome biogenesis. Kleinman CL, Doria M, Orecchini E, Giuliani E, Galardi S, De Jay N, Michienzi A. ***PLoS One.*** 2014 Dec 2;9(12):e113908.
- 22.** The ADAR1 editing enzyme is encapsidated into HIV-1 virions. Orecchini E, Federico M, Doria M, Arenaccio C, Giuliani E, Ciafrè SA, Michienzi A. ***Virology.*** 2015 Nov;485:475-80.
- 23.** CPEB1 restrains proliferation of Glioblastoma cells through the regulation of p27(Kip1) mRNA translation. Galardi S, Petretich M, Pinna G, D'Amico S, Loreni F, Michienzi A, Groisman I, Ciafrè SA. ***Sci Rep.*** 2016 May 4;6:25219.

- 24.** ADAR1 restricts LINE-1 retrotransposition.Orecchini E, Doria M, Antonioni A, Galardi S, Ciafrè SA, Frassinelli L, Mancone C, Montaldo C, Tripodi M, **Michienzi A.** *Nucleic Acids Res.* 2017 Sep 21. pii: gkw834.
- 25.** Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, **Michienzi A**, Andreoni M, Franciosi S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, Svicher V. **Oncotarget**. 2017 Feb 28;8(9):15704-15715. doi: 10.18632/oncotarget.14944.
- 26.** "Resetting cancer stem cell regulatory nodes upon MYC inhibition". Silvia Galardi, Mauro Savino, Fiorella Scagnoli, Serena Pellegatta, Federica Pisati, Federico Zambelli, Barbara Illi, Daniela Annibali, Sara Beji, Elisa Orecchini, Maria Adele Alberelli, Clara Apicella, Rosaria Fontanella, **Alessandro Michienzi**, Gaetano Finocchiaro, Maria Farace, Giulio Pavesi, Silvia Ciafrè, and Sergio Nasi **EMBO REPORT** - 2016 Dec;17(12):1872-1889.
- 27.** Restricting retrotransposons: ADAR1 is another guardian of the human genome. Orecchini E, Frassinelli L, **Michienzi A** (2017). **RNA BIOLOGY**, vol. 14, p. 1485-1491, ISSN: 1547-6286, doi: 0.1080/15476286.2017.1341033.
- 28.** Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases. Orecchini E, Frassinelli L, Galardi S, Ciafrè SA, **Michienzi A.** *Chromosome Res.* 2018 Mar;26(1-2):45-59. doi: 10.1007/s10577-018-9572-5. Epub 2018 Feb 2. Review.
- 29.** The lncRNA H19 positively affects the tumorigenic properties of glioblastoma cells and contributes to NKD1 repression through the recruitment of EZH2 on its promoter. Fazi B, Garbo S, Toschi N, Mangiola A, Lombardi M, Sicari D, Battistelli C, Galardi S, **Michienzi A**, Trevisi G, Harari-Steinfeld R, Cicchini C, Ciafrè SA. **Oncotarget**. 2018 Feb 14;9(21):15512-15525. doi: 10.18632/oncotarget.24496. eCollection 2018 Mar 20.
- 30.** Dual regulation of L-selectin (CD62L) by HIV-1: Enhanced expression by Vpr in contrast with cell-surface down-modulation by Nef and Vpu. Giuliani E, Vassena L, Galardi S, **Michienzi A**, Desimio MG, Doria M. **Virology**. 2018 Oct;523:121-128. doi: 10.1016/j.virol.2018.07.031.
- 31.** The Expression of the Chemokine CXCL14 Correlates with Several Aggressive Aspects of Glioblastoma and Promotes Key Properties of Glioblastoma Cells. Fazi B, Proserpio C, Galardi S,

Annesi F, Cola M, Mangiola A, **Michienzi A**, Ciafrè SA. **Int J Mol Sci.** 2019 May 21;20(10):2496. doi: 10.3390/ijms20102496.

**32.** Insights into the Regulatory Role of m6A Epitranscriptome in Glioblastoma.

Galardi S, **Michienzi A**, Ciafrè SA. **Int J Mol Sci.** 2020 Apr 17;21(8):2816. doi: 10.3390/ijms21082816.

**33.** RNA Editing in Interferonopathies. Frassinelli L, Galardi S, Ciafrè SA, **Michienzi A**. **Methods Mol Biol.** 2021;2181:269-286. doi: 10.1007/978-1-0716-0787-9\_16.

**34.** The RNA editing enzyme ADAR2 restricts L1 mobility. Frassinelli L, Orecchini E, Al-Wardat S, Tripodi M, Mancone C, Doria M, Galardi S, Ciafrè SA, **Michienzi A**. **RNA Biol.** 2021 Oct 15;18(sup1):75-87. doi:10.1080/15476286.2021.1940020

**35.** MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia. Proserpio C, Galardi S, Desimio MG, **Michienzi A**, Doria M, Minutolo A, Matteucci C, Ciafrè SA. **Cancers (Basel).** 2022 May 6;14(9):2304. doi: 10.3390/cancers14092304.

**36.** Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures. Babačić H, Galardi S, Umer HM, Hellström M, Uhrbom L, Maturi N, Cardinali D, Pellegatta S, **Michienzi A**, Trevisi G, Mangiola A, Lehtiö J, Ciafrè SA, Pernemalm M. **Mol Oncol.** 2023 Feb;17(2):238-260. doi: 10.1002/1878-0261.13355.

**37.** Long Noncoding RNAs and Cancer Stem Cells: Dangerous Liaisons Managing Cancer.

Ciafrè SA, Russo M, **Michienzi A**, Galardi S. **Int J Mol Sci.** 2023 Jan 17;24(3):1828. doi: 10.3390/ijms24031828.

**38.** An essential role of adenosine deaminase acting on RNA 1 in coeliac disease mucosa.

Di Fusco D, Segreto MT, Iannucci A, Maresca C, Franzè E, Di Maggio G, Di Grazia A, Boccanera S, Laudisi F, Marafini I, Paoluzi OA, **Michienzi A**, Monteleone G, Monteleone I. **Front Immunol.** 2023 May 8;14:1175348. doi: 10.3389/fimmu.2023.1175348.

**39.** Characterization of the molecular dysfunctions occurring in Aicardi-Goutières syndrome patients with mutations in ADAR1. Sofian Al Wardat, Loredana Frassinelli, Elisa Orecchini, Federica Rey, Silvia Anna Ciafrè, Silvia Galardi, Jessica Garau, Stella Gagliardi, Simona Orcesi, Davide Tonduti, Stephana Carelli, Cristina Cereda, Ernesto Picardi, **Alessandro Michienzi**.

**Genes Dis.** 2023 Jul 13;11(3):101028. doi: 10.1016/j.gendis.2023.05.020.

## BREVETTI

**1.** Patent number: RM97A000150

Titolo: Chimeric ribozyme-scRNA catalytic RNA molecule with cytoplasmatic localization

Inventori: Irene Bozzoni, Silvia Prislei, Sara C.B. Buonomo **Alessandro Michienzi**

Data: 3/17/1997

**2.** Patent number: RM99A000126

Title: Chimeric RNA molecule with nucleolar localization able to bind HIV-1 Rev protein

Inventori: Irene Bozzoni, **Alessandro Michienzi**, Sara C.B. Buonomo. Data: 2/24/1999.

**3.** Patent number: US Patent 8,227,442 B2

Title: Nucleolar Targeting of Therapeutics Against HIV

Inventori: John Rossi, **Alessandro Michienzi** Data: 24/07/2012